FDA Approves Boston Scientific’s Ranger Drug-Coated Balloon

Boston Scientific received U.S. Food and Drug Administration (FDA) approval of the Ranger Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).  
 
Approximately 200 million people around the world are affected by PAD¹, a common circulatory problem in which plaque builds up and narrows arteries, consequently reducing blood flow to limbs. The Ranger DCB was designed with a low therapeutic drug dose and proprietary coating which efficiently transfers the drug into the tissue, resulting in high primary patency rates and low systemic drug exposure for patients. The low-profile platform of the balloon also assists clinicians in performing streamlined procedures and navigating through challenging anatomy in order to deliver consistent therapy.
 
“This approval allows us to bring more treatment options with exceptional outcomes and proven safety to U.S. physicians and their patients who are facing this challenging disease,” said Jeff Mirviss, president, Peripheral Interventions, Boston Scientific. “Adding the Ranger DCB to our drug-eluting portfolio, which also includes our Eluvia Drug-Eluting Vascular Stent System, reinforces our commitment to providing differentiated technology with strong clinical evidence that supports data-driven treatment decisions for millions of patients suffering from PAD worldwide.”
 
The FDA approval is based on results from the RANGER II SFA pivotal trial, which evaluated the safety and effectiveness of the Ranger DCB versus standard percutaneous transluminal angioplasty (PTA) for the treatment of patients with PAD in the SFA and PPA. In the randomized controlled trial, both primary endpoints were met:
 

• The primary safety endpoint of 12-month freedom from major adverse events (MAE) was 94.1 percent for those treated with the Ranger DCB versus 83.5 percent for standard PTA (Pnon-inferiority <0.0001).²
• Additionally, patients who received therapy with the Ranger DCB had a significantly lower target lesion revascularization rate—a component of MAE—of 5.5 percent in contrast to 16.5 percent observed with standard PTA (p=0.0011), substantially reducing a patient’s need for repeat procedures.²
• The primary efficacy endpoint of 12-month binary primary patency—a measure of the target vessel remaining unobstructed—was 82.9 percent for the Ranger DCB and 66.3 percent for standard PTA (p=0.0017). Primary patency by Kaplan-Meier estimate was 89.8 percent for the Ranger DCB and 74.0 percent for PTA at 12 months (p=0.0005).²

 
“The Ranger DCB eases deliverability for a wide range of lesion complexities via a low profile platform that is compatible with smaller diameter guidewires and has shown consistent results in multiple randomized controlled trials,” said Ravish Sachar, M.D., UNC Rex Hospital Physician-in-Chief for Heart and Vascular services and principal investigator of the RANGER II SFA trial. “For physicians seeking to limit systemic drug loss without compromising outcomes, data demonstrate the Ranger DCB is a safe and effective treatment option.”
 
The Ranger DCB also demonstrated nearly 90 percent primary patency in the investigator-sponsored COMPARE trial³—the first head-to-head prospective, randomized controlled trial to compare two different DCBs. In the trial, the Ranger DCB demonstrated a similar primary patency rate of 88.4 percent to that of the 89.4 percent observed with IN.PACT Admiral Drug-Coated Balloon (Medtronic) by Kaplan-Meier estimate (p=0.81), with a significantly lower drug dose density (2 µg/mm² paclitaxel versus 3.5 µg/mm² paclitaxel, respectively).^3,4
 
Boston Scientific expects to initiate a registry of the Ranger DCB and the Eluvia stent in the coming months to gather additional real-world evidence, which will add to the breadth of clinical data collected on these devices to date. The registry is expected to include five years of patient follow-up with an emphasis on enrolling patient populations who have been historically underrepresented in clinical trials studying treatments for PAD. 
 
The company announced CE mark for the Ranger DCB in 2014 and plans to immediately launch the device in the U.S.
 
References
¹ Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379-381.
² RANGER II SFA Pivotal Trial 12-Month Results presented by Marianne Brodmann, M.D. LINC 2020. 12-Month Primary Endpoints: Binary Primary Patency = 82.9 percent for Ranger DCB and 66.3 percent for PTA (p= <0.0017). Freedom from Major Adverse Events = 94.1 percent for Ranger DCB and 83.5 percent for PTA (p <0.0001)
³ COMPARE Clinical Trial 12-Month Results presented by Sabine Steiner, M.D. LINC 2020. 12-Month Primary Endpoints: Binary Primary Patency = 83.0 percent for Ranger DCB and 81.5 percent for IN.PACT DCB (p <0.01). Freedom from Major Adverse Events = 91.0 percent for Ranger DCB and 92.6 percent for IN.PACT DCB (p<0.01).
⁴ Based on total drug dose for 4mmx60mm or averages for full size matrix per the IN.PACT Admiral Drug-Coated Balloon Instructions for Use, www.medtronic.com and the Ranger Drug-Coated Balloon Instructions for Use.